Focus Taiwan App
Download

NHI to cover NT$49 million gene therapy drug for muscle atrophy

06/24/2023 10:00 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

A one-time-only drug to treat spinal muscular atrophy (SMA) that will cost NT$49 million (US$1.58 million) will soon be covered for infants six months old and under by Taiwan's universal health insurance system.


(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.
    62